Analysis of serum EPO levels is performed in two main clinical contexts; firstly to distinguish between primary and secondary polycythaemias and, secondly, to assess the need for recombinant human EPO (r-HuEPO) replacement therapy, primarily in cases of chronic kidney disease (CKD)11–13. The gene discussed is EPO; the disease is chronic kidney disease.